DOE OSTI · 3576303
Alternative Structural Lipids Impact mRNA-Lipid Nanoparticle Morphology, Stability, and Activity
Abstract
The source did not provide an abstract. Follow the original record for more information.
Keep this discovery
Explore connections, maps & timelines
Thorn, Chelsea R. [BioTherapeutics Pharmaceutical Sciences; Pharmaceutical Research and Development, Pfizer Inc.], Hickey, James Collin [BioMedicine Design, Pfizer Inc.], Chi, Ying-Chih [BioTherapeutics Pharmaceutical Sciences, Analytical Research and Development, Pfizer Inc.], Wang, Mingzhang Maple [BioTherapeutics Pharmaceutical Sciences, Analytical Research and Development, Pfizer Inc.], Ng Huang, Karina [Vaccines Research and Development, Pfizer Inc.], Hong, Sue-Jean [Vaccines Research and Development, Pfizer Inc.], Zou, Qin [BioTherapeutics Pharmaceutical Sciences, Analytical Research and Development, Pfizer Inc.], Nguyen, Hong-My [Drug Safety Research & Development, Pfizer Inc], Pak, Roger H. [BioTherapeutics Pharmaceutical Sciences; Pharmaceutical Research and Development, Pfizer Inc.], Lim Soo, Patrick [BioTherapeutics Pharmaceutical Sciences; Pharmaceutical Research and Development, Pfizer Inc.] (ORCID:0009000134779222). 2025-11-26. Alternative Structural Lipids Impact mRNA-Lipid Nanoparticle Morphology, Stability, and Activity. https://doi.org/10.1021/acs.molpharmaceut.5c00824
Cite the original work for its findings. Save a collection to share your selection of sources.